Entering text into the input field will update the search result below

Aveo Oncology to host conference call to discuss trial results

Feb. 27, 2015 7:38 AM ETAVEO Pharmaceuticals, Inc. (AVEO) StockAVEOBy: Douglas W. House, SA News Editor
  • Aveo Oncology (NASDAQ:AVEO) will conduct a conference call on March 6 at 8:00 am ET to discuss the results from the Phase 2 BATON-CRC study of modified FOLFOX6 in combination with tivozanib or bevacizumab (Avastin) in metastatic colorectal cancer.
  • Tivozanib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor that suppresses angiogenesis and "starves" a tumor. It was being developed under a joint collaboration with Astellas Pharma that was established in February 2011, but Astellas ended the partnership ~ one year ago for strategic reasons.
  • Investigators will present the results on the same day at the American Association for Cancer Research Tumor Angiogenesis and Vascular Normalization Conference in Orlando, FL.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
AVEO--
AVEO Pharmaceuticals, Inc.